Alkermes
NASDAQ: ALKSFounded 1987 · 2,446 employees on LinkedIn · 4 known investors
Find your way into Alkermes
Sign up to see every warm intro you have to Alkermes
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alkermes team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders. The company leverages neuroscience expertise to create treatments for patients with complex conditions that are traditionally underserved.
Founders & leadership




Investors · 4
How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us
How we know: Cardinal Partners's portfolio page · Not right? Tell us
How we know: Vedanta Capital's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Founder mafia
3 people who came through Alkermes went on to found or lead other companies.
Related companies · 1
Companies working in the same space as Alkermes.
In the news
Frequently asked questions
- What does Alkermes do?
- Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders. The company leverages neuroscience expertise to create treatments for patients with complex conditions that are traditionally underserved.
- Who are Alkermes's investors?
- Alkermes's investors include Bain Capital Life Sciences, Cardinal Partners, Vedanta Capital, Hatteras Venture Partners.








